Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shingles pain breakthrough? injections may beat standard drugs

NCT ID NCT06344403

Symptom relief Sponsor: Beijing Tiantan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether injecting a mix of lidocaine and steroids into tender points can better relieve shingles pain compared to standard painkillers alone. The trial involves 136 adults with severe shingles pain for less than 90 days. Researchers will track pain levels for up to 12 months to see if the injections reduce the chance of long-term nerve pain.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lidocaine and diprospan (steroid) injected into tender points
What this could lead to
If it works, this could offer a more effective way to manage shingles pain and reduce the risk of long-term nerve pain.
What could go wrong
This is a small, early-stage trial with no phase designation, so results may not be conclusive. The injections carry risks like infection or allergic reaction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 136 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with onset of HZ rash less than 90 days. 2. HZ affected the spinal nerves (cervical/thoracic/lumbar nerve). 3. Aged 18 to 75 years (inclusive). 4. Pain intensity \> 7 cm on a visual analogue scale (VAS 0-10 cm). 5. Agreed to sign the informed consent form. Exclusion Criteria: 1. Infection at the puncture site. 2. Poor general situation unable to be treated. 3. A history of abuse of narcotics. 4. Non-compliance or inability to complete the self-evaluation questionnaires. 5. Pregnancy or lactation. 6. Patients using immunosuppressants and those with severe systemic diseases such as hematological malignancies, cancers, or autoimmune disorders.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Acute Pain herpes zoster

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute pain Herpes zoster Local infiltration

Contacts and locations

Locations

  • Beijing Tiantan Hospital

    Beijing, Beijing Municipality, 100070, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.